A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs)

PHASE3CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

July 31, 2008

Conditions
Facial Wrinkles at the Nasolabial Folds
Interventions
DEVICE

Dermal Gel Extra (DGE)

Dermal Gel Extra (DGE) Injectable Gel contains hyaluronic acid with lidocaine. DGE was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of DGE to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.

DEVICE

Restylane

Restylane was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of Restylane to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.

DRUG

EMLA Cream

EMLA Cream (Eutectic Mixture of Local Anesthetics) is an FDA-approved topical anesthetic comprised of 2.5% each of lidocaine/prilocaine. EMLA Cream was applied in approximately equal amounts prior to all injections of DGE and Restylane.

Trial Locations (6)

10640

White Plains

33140

Miami Beach

35205

Birmingham

37215

Nashville

92037

La Jolla

07675

Westwood

All Listed Sponsors
collaborator

Mentor Worldwide, LLC

INDUSTRY

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00444626 - A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs) | Biotech Hunter | Biotech Hunter